SCHEMBL19699052

SCHEMBL19699052

Cc1cccc(-c2ccc3c(n2)N(C(=O)Nc2cccnc2)[C@@H]2CCCN3C2)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 6/20 0.44
▸ HTR2C P28335 6/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ KMT2A Q03164 1/20 0.42
▸ TSHR P16473 1/20 0.41
▸ PIM3 Q86V86 1/20 0.41
▸ PIM2 Q9P1W9 1/20 0.41
▸ BTK Q06187 2/20 0.40
▸ GAA P10253 1/20 0.39
▸ CACNA1G O43497 1/20 0.39
▸ CACNA1H O95180 1/20 0.39
▸ CACNA1I Q9P0X4 1/20 0.39
▸ CNR1 P21554 2/20 0.38
▸ ABL1 P00519 2/20 0.38
▸ BCR P11274 2/20 0.38
▸ PIM1 P11309 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19699063 1.00 HTR2A (0.44) HTR2AHTR2CALDH1A1MAPTKMT2A
SCHEMBL19699039 0.95 HTR2C (0.46) HTR2AHTR2CALDH1A1MAPTGAA
SCHEMBL17618725 0.92 ALDH1A1 (0.43) HTR2AHTR2CALDH1A1MAPTKMT2A
SCHEMBL17618673 0.92 PIM3 (0.47) HTR2AHTR2CALDH1A1MAPTPIM3
SCHEMBL19699050 0.91 KMT2A (0.41) ALDH1A1MAPTKMT2ATSHRPIM3
SCHEMBL17618630 0.90 TSHR (0.45) HTR2AHTR2CALDH1A1MAPTKMT2A
SCHEMBL16776482 0.89 ALDH1A1 (0.42) HTR2AHTR2CALDH1A1MAPTPIM3
SCHEMBL20733261 0.89 KMT2A (0.42) HTR2AHTR2CALDH1A1MAPTKMT2A
SCHEMBL17618719 0.88 ALDH1A1 (0.42) HTR2AHTR2CALDH1A1MAPTKMT2A
SCHEMBL19365515 0.88 HTR2C (0.47) HTR2AHTR2CALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2017-12-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 HTR2A 4386/4885HTR2C 4651/4885ALDH1A1 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback